4.4 Article

Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Critical Care Medicine

Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis

Jose Nunez et al.

Summary: This study aimed to analyze the prevalence, mortality association, and risk factors for bleeding and thrombosis events among adults supported with venovenous extracorporeal membrane oxygenation. Bleeding and thrombotic events are common during VV-ECMO and have a strong, cumulative association with in-hospital mortality. While thrombotic events are more frequent, bleeding carries a higher risk of inpatient mortality. Differential risk factors for bleeding and thrombotic complications exist, suggesting the possibility of a tailored approach to VV-ECMO management.

INTENSIVE CARE MEDICINE (2022)

Article Pharmacology & Pharmacy

A role for nebulized tranexamic acid in veno-venous ECMO patients

M. Gabriela Cabanilla et al.

Summary: This case series demonstrates successful bleeding management with nebulized tranexamic acid, reducing the frequency of ECMO circuit changes, time off of anticoagulation and blood loss.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

Article Engineering, Biomedical

Heparin-Free Lung Transplantation on Venovenous Extracorporeal Membrane Oxygenation Bridge

Vittorio Scaravilli et al.

Summary: The use of a novel no-heparin management approach during ECMO bridging to lung transplantation (LuTX) can effectively reduce the risk of perioperative bleeding, even in high-risk patients. Prospective studies are needed to further validate the effectiveness of this strategy.

ASAIO JOURNAL (2021)

Article Pediatrics

Epidemiology of the Use of Hemostatic Agents in Children Supported by Extracorporeal Membrane Oxygenation: A Pediatric Health Information System Database Study

Marianne E. Nellis et al.

Summary: Children supported by ECMO receive a significant number of hemostatic blood products, with a rising trend in the use of antifibrinolytics such as TXA. Further studies are needed to evaluate the effectiveness of these hemostatic strategies.

FRONTIERS IN PEDIATRICS (2021)

Review Hematology

Tranexamic acid evidence and controversies: An illustrated review

Nicole Relke et al.

Summary: Tranexamic acid (TXA) is a commonly used antifibrinolytic agent for the treatment or prevention of bleeding, with indications ranging from heavy menstrual bleeding to traumatic brain injury. Despite robust evidence, hesitancy in using TXA persists in many clinical settings.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)

Article Emergency Medicine

Tracheostomy Emergencies

Laura J. Bontempo et al.

EMERGENCY MEDICINE CLINICS OF NORTH AMERICA (2019)

Article Engineering, Biomedical

Therapeutic Interventions and Risk Factors of Bleeding During Extracorporeal Membrane Oxygenation

Christopher Lotz et al.

ASAIO JOURNAL (2017)

Review Clinical Neurology

Tranexamic Acid-Associated Seizures: Causes and Treatment

Irene Lecker et al.

ANNALS OF NEUROLOGY (2016)

Article Critical Care Medicine

Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation

Cecile Aubron et al.

ANNALS OF INTENSIVE CARE (2016)

Article Cardiac & Cardiovascular Systems

Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score

Matthieu Schmidt et al.

EUROPEAN HEART JOURNAL (2015)

Review Hematology

Extracorporeal Membrane Oxygenation-Hemostatic Complications

Deirdre A. Murphy et al.

TRANSFUSION MEDICINE REVIEWS (2015)

Article Critical Care Medicine

Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy

Michael P. Chapman et al.

JOURNAL OF TRAUMA AND ACUTE CARE SURGERY (2013)